Concerns about Wave Life Sciences WVE-003 safety ‘overblown,’ says Mizuho

Mizuho notes that Wave Life Sciences announced results from its Phase 1b/2a SELECT-HD clinical trial of WVE-003 as a potential disease modifying therapeutic for Huntington’s disease, or HD, and held an associated call. WVE-003 delivered on mHTT, “perhaps exceeding expectations,” and wtHTT sparing, says the analyst, who adds that “some pushback so far” on safety is “overblown” given the context of a severe disease with no real treatment or cure. The firm maintains an Outperform rating and $19 price target on Wave Life Sciences shares.